ASA404
Phase 1Terminated 0 views this week 0 watching💤 Quiet
Interest: 21/100
21
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Metastatic Cancer With Impaired Renal Function
Conditions
Metastatic Cancer With Impaired Renal Function, Metastatic Cancer With Normal Renal Function
Trial Timeline
Jan 1, 2010 → —
NCT ID
NCT01240642About ASA404
ASA404 is a phase 1 stage product being developed by Novartis for Metastatic Cancer With Impaired Renal Function. The current trial status is terminated. This product is registered under clinical trial identifier NCT01240642. Target conditions include Metastatic Cancer With Impaired Renal Function, Metastatic Cancer With Normal Renal Function.
What happened to similar drugs?
20 of 20 similar drugs in Metastatic Cancer With Impaired Renal Function were approved
Approved (20) Terminated (8) Active (0)
Hype Score Breakdown
Clinical
6
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01240642 | Phase 1 | Terminated |
| NCT01278849 | Phase 1 | Terminated |
| NCT01299701 | Phase 1 | Terminated |
| NCT00674102 | Phase 1 | Completed |
Competing Products
20 competing products in Metastatic Cancer With Impaired Renal Function